Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study

被引：0
|
作者：
Silberstein, Stephen D. [1 ]
Ashina, Messoud [2 ]
Cohen, Joshua M. [3 ]
Seminerio, Michael J. [3 ]
Yang, Ronghua [3 ]
Ning, Xiaoping [3 ]
Ortega, Mario [3 ]
机构：
[1] Thomas Jefferson Univ, Jefferson Headache Ctr, Philadelphia, PA 19107 USA
[2] Univ Copenhagen, Copenhagen, Denmark
[3] Teva Pharmaceut, Frazer, PA USA
来源：
ANNALS OF NEUROLOGY | 2019年 / 86卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
S194
引用
收藏
页码：S76 / S76
页数：1
相关论文
共 50 条
  • [1] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Silberstein, S. D.
    Ashina, M.
    Cohen, J. M.
    Seminerio, M. J.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 95 - 96
  • [2] Long-Term term efficacy of fremanezumab in chronic and episodic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Silberstein, Stephen D.
    Ashina, Messoud
    Cohen, Joshua M.
    Seminerio, Michael J.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 234 - 235
  • [3] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in episodic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Lipton, Richard M.
    Turner, Ira
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Elms, Shawn
    CEPHALALGIA, 2019, 39 : 247 - 248
  • [4] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Episodic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Lipton, R. B.
    Turner, I. M.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 114
  • [5] Long-term impact of fremanezumab on response rate, acute headache medication use, and disability in chronic migraine patients with acute medication overuse at baseline: results of a 1-year study
    Silberstein, Stephen D.
    Kudrow, David
    Cohen, Joshua M.
    Gandhi, Sanjay K.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 214 - 214
  • [6] Long-Term Impact of Fremanezumab on Response Rate, Acute Headache Medication Use, and Disability in Chronic Migraine Patients with Acute Medication Overuse at Baseline: Results of a 1-Year Study
    Silberstein, S. D.
    Kudrow, D.
    Cohen, J. M.
    Gandhi, S. K.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 113 - 113
  • [7] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, P. K.
    Freeman, M. C.
    Cohen, J. M.
    Yang, R.
    Ning, X.
    HEADACHE, 2019, 59 : 118 - 119
  • [8] Long-term efficacy of fremanezumab in chronic and episodic migraine patients who failed at least one prior migraine preventive medication: results of a 1-year study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Blaiss, Cory
    CEPHALALGIA, 2019, 39 : 36 - 37
  • [9] Long-Term Efficacy of Fremanezumab in Chronic and Episodic Migraine Patients Who Failed at Least One Prior Migraine Preventive Medication: Results of a 1-Year Study
    Winner, Paul K.
    Freeman, Marshall C.
    Cohen, Joshua M.
    Yang, Ronghua
    Ning, Xiaoping
    Ortega, Mario
    ANNALS OF NEUROLOGY, 2019, 86 : S168 - S169
  • [10] Long-Term Efficacy and Safety of Fremanezumab in Migraine: Results of a 1-Year Study
    Goadsby, P. J.
    Monteith, T.
    Cohen, J. M.
    Yang, R.
    HEADACHE, 2019, 59 : 99 - 99
12345